Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Source: View publication →
In patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer, the addition of abiraterone acetate and prednisone to androgen deprivation therapy significantly improved overall survival compared to placebo plus androgen deprivation therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial established the combination of abiraterone acetate and prednisone with androgen deprivation therapy as a standard of care for patients with high-risk metastatic castration-sensitive prostate cancer, providing a robust survival benefit that shifted treatment paradigms toward earlier aggressive intervention.
Historical Context
Prior to LATITUDE and the concurrent STAMPEDE trial results, the standard of care for metastatic castration-sensitive prostate cancer was androgen deprivation therapy (ADT) alone. These landmark trials demonstrated that intensifying treatment with either docetaxel or abiraterone at the time of initial diagnosis significantly improves outcomes, moving beyond the traditional use of these agents only after the development of castration resistance.
Guided Discussion
High-yield insights from every perspective
What is the biochemical mechanism by which abiraterone acetate treats metastatic prostate cancer, and why must it be co-administered with a glucocorticoid like prednisone?
Key Response
Abiraterone acetate is a potent inhibitor of CYP17A1 (17̡-hydroxylase and C17,20-lyase), an enzyme required for androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissue. By blocking this enzyme, it also blocks cortisol synthesis. The resulting rise in adrenocorticotropic hormone (ACTH) due to lack of feedback inhibition leads to mineralocorticoid excess (causing hypertension, hypokalemia, and fluid retention). Prednisone is added to provide physiological glucocorticoid replacement and suppress ACTH levels, thereby mitigating these side effects.
The LATITUDE trial specifically targeted 'high-risk' metastatic castration-sensitive prostate cancer (mCSPC). What are the three specific clinical criteria used to define 'high-risk' in this study, and how many must a patient meet to qualify?
Key Response
To qualify for the LATITUDE trial, patients had to meet at least two of the following three high-risk criteria: (1) a Gleason score of 8 or higher, (2) the presence of three or more bone lesions on bone scan, or (3) the presence of measurable visceral metastasis (excluding nodal disease). Identifying this cohort is essential because they have a poorer prognosis and derive significant benefit from early treatment intensification beyond androgen deprivation therapy (ADT) alone.
In the final OS analysis of LATITUDE, the placebo group had a high rate of subsequent life-prolonging therapies (including abiraterone and docetaxel) upon progression. Discuss how this 'crossover' affects the interpretation of the hazard ratio for overall survival.
Key Response
Extensive post-progression therapy in the control arm (roughly 52% in the final analysis) typically biases the treatment effect toward the null, making it harder to demonstrate a statistically significant difference in overall survival (OS). Despite this 'dilution' effect, the LATITUDE trial showed a robust OS benefit (HR 0.66), emphasizing that early intensification in the hormone-sensitive state is superior to waiting until the development of castration-resistance (mCRPC) to initiate these therapies.
With the emergence of triplet therapy (ADT + docetaxel + ARPI) in trials like PEACE-1 and ARASENS, for which high-risk mCSPC patient would you still consider the LATITUDE doublet regimen (ADT + abiraterone) as the preferred standard of care?
Key Response
While triplet therapy is becoming the new standard for fit, high-volume/high-risk patients, the LATITUDE doublet remains preferred for patients who are not candidates for chemotherapy due to poor performance status, significant comorbidities (e.g., neuropathy, brittle bone marrow), or patient preference to avoid the toxicities of docetaxel (alopecia, febrile neutropenia). It remains a cornerstone of treatment for those seeking a purely oral-based intensification strategy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Evaluate the use of radiographic progression-free survival (rPFS) as a co-primary endpoint in the LATITUDE trial. Does rPFS serve as a reliable surrogate for overall survival in mCSPC research, and how does this affect trial design?
Key Response
While rPFS is a meaningful clinical milestone and often allows for earlier data readout, its status as a formal surrogate for OS in prostate cancer remains a subject of statistical debate. In mCSPC, the long tail of survival post-progression means rPFS might not always perfectly correlate with OS. However, by using co-primary endpoints, LATITUDE demonstrated that the early treatment effect on tumor burden (rPFS) was substantial enough to translate into a definitive 34% reduction in the risk of death, validating the clinical utility of targeting the androgen receptor pathway early.
A major criticism of many mCSPC trials is the 'moving target' of the control arm. Given that docetaxel (CHAARTED/STAMPEDE) became standard of care during the LATITUDE enrollment, how does the use of an ADT-only control arm impact the journal's assessment of the study's internal versus external validity?
Key Response
Internal validity remains high because the trial was randomized and double-blinded against the global standard at the time of initiation. However, external validity (generalizability) is challenged because the 'real-world' question shifted from 'Is Abiraterone better than ADT alone?' to 'Is Abiraterone better than Docetaxel?' or 'Should we use both?'. Editors must weigh whether the trial provides a definitive answer for a patient population where chemotherapy might not be the chosen or available comparator.
Based on the final OS results of LATITUDE, how should the strength of recommendation for abiraterone in mCSPC be categorized in clinical guidelines, and how does it compare to the recommendations for other ARPIs like enzalutamide or apalutamide?
Key Response
LATITUDE provides Level 1 evidence for the use of abiraterone in high-risk mCSPC, leading to a 'Strong' recommendation in NCCN, EAU, and ASCO guidelines. While enzalutamide (ARCHES/ENZAMET) and apalutamide (TITAN) also hold strong recommendations based on their respective trials, abiraterone is uniquely associated with the 'high-risk' subgroup definition. Current guidelines generally view these ARPIs as interchangeable in terms of efficacy for mCSPC, leaving the choice to be driven by side-effect profiles (e.g., steroids vs. rash/fatigue) and cost.
Clinical Landscape
Noteworthy Related Trials
CHAARTED Trial
Tested
Docetaxel plus androgen-deprivation therapy
Population
Patients with metastatic hormone-sensitive prostate cancer
Comparator
Androgen-deprivation therapy alone
Endpoint
Overall survival
STAMPEDE Trial
Tested
Abiraterone acetate and prednisolone plus standard of care
Population
Patients with locally advanced or metastatic prostate cancer starting long-term androgen-deprivation therapy
Comparator
Standard of care alone
Endpoint
Overall survival
ARCHES Trial
Tested
Enzalutamide plus androgen-deprivation therapy
Population
Patients with metastatic hormone-sensitive prostate cancer
Comparator
Placebo plus androgen-deprivation therapy
Endpoint
Radiographic progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis